Arylesterase activity of paraoxonase 1 and intensity of oxidative processes in the blood of dialysis patients

  • L. Korol State Institution «Institute of Nephrology of the National Academy of Medical Sciences of Ukraine» http://orcid.org/0000-0002-5484-0326
  • N. Stepanova State Institution «Institute of Nephrology of the National Academy of Medical Sciences of Ukraine» https://orcid.org/0000-0002-1070-3602
  • V. Vasylchenko State Institution «Institute of Nephrology of the National Academy of Medical Sciences of Ukraine»
DOI: https://doi.org/10.31450/ukrjnd.4(64).2019.05
Keywords: paraoxonase-1, arylesterase, oxidative stress, end-stage renal disease.

Abstract

This study aimed to investigate the arylesterase activity of paraoxonase 1 (PON-1) in patients with end-stage renal disease (ESRD) and its relationship with oxidative stress markers.

Methods. We conducted a one-time prospective observational study involving 58 ESRD patients. Among them, there were 20 hemodialyses (HD) patients and 38 patients treated with peritoneal dialysis (PD). The activity of PON-1 in serum was determined spectrophotometrically by the number of phenolic complexes formed using phenylacetate. Besides, spectrophotometrically the concentrations of malondialdehyde, serum concentrations of ceruloplasmin, thiol groups and total peroxidase activity (TPA) of erythrocyte were determined. The reference group consisted of 30 conditionally healthy individuals.

Results. The arylesterase activity of the PON-1 in reference group was 6.57 kU/L versus 2.25 kU/L in HD patients and 4.26 kU/L in PD patients (p ˂ 0.0001). A direct correlation was found between arylesterase activity of PON-1 and ceruloplasmin concentration (p = 0.004), and TPA (p = 0.02) in HD patients. The activity of PON-1 in the serum of PD patients was associated with high-density lipoproteins (p ˂ 0.0001).

Conclusions. We observed a decrease in the arylesterase activity of PON-1 in ESRD patients compared to the control group. The lowest activity of PON-1 is determined in HD patients. Moreover, the association of the PON-1 activity with a decrease in antioxidant blood markers was found. The enzyme activity in PD patients correlated with increased blood HDL. Further studies involving a larger dialysis cohort of patients are needed to determine the pathogenetic role of PON-1 activity in the development of cardiovascular events in ESRD patients.

Downloads

Download data is not yet available.

References

1. Ku E, Mitsnefes MM. Cardiovascular disease in young adults with incident ESRD. Nat Rev Nephrol 2019; 15(7): 390-1. PMID: 31043718. doi: 10.1038/s41581-019-0154-3

2. Duni A, Liakopoulos V, Rapsomanikis KP, Dounousi E.  Chronic Kidney Disease and Disproportionally Increased Cardiovascular Damage: Does Oxidative Stress Explain the Burden? Oxidative Medicine and Cellular Longevity 2017. doi: 10.1155/2017/9036450.

3. Okuturlar Y, Akalin N, Kaptanogullari OH, Guner NT, Yilmaz D, Gedikbasi A et al. Comparison of serum paraoxonase and arylesterase activities between iron deficiency anemia patients and chronic kidney disease patients with anemia. Ren Fail 2016;38(5):781-6. doi: 10.3109/0886022X.2016.1162080.

4. Efe TH, Ertem AG, Altunoglu A, Koseoglu C, Erayman A, Bilgin M, et al. Paraoxonase Levels are Correlated with Impaired Aortic Functions in Patients with Chronic Kidney Disease. Acta Cardiol Sin 2016; 32(1): 75–80. doi: 10.6515/ACS20150429A.

5. Mohammed CJ, Xie Y, Brewster PS, Ghosh S, Dube P, Sarsour T, et al. Circulating Lactonase Activity but Not Protein Level of PON-1 Predicts Adverse Outcomes in Subjects with Chronic Kidney Disease. J Clin Med 2019; 8(7).  doi: 10.3390/jcm8071034.

6. Gugliucci A , Kotani K , Kimura S.  Paraoxonase 1 in chronic kidney failure. Journal of Lipids 2012. doi: 10.1155/2012/726048.

7. Suematsu Y, Goto M, Park C, Nunes A, Wang HJ, Streja E, et al. Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients. The Journal of Clinical Endocrinology & Metabolism 2019; 104(10):4848-56. doi: 10.1210/jc.2019-00334

8. Samouilidou E, Kostopoulos V, Liaouri A, Kioussi E, Vassiliou K, Bountou E , et. al. Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease. Ren Fail 2016; 38(10):1601-6.  doi:  10.3109/0886022X.2016.1144031.

9. Chang TI, Streja E, Soohoo M, Kim TW, Rhee CM, Kovesdy CP, Kashyap ML, Vaziri ND, Kalantar-Zadeh K, Moradi H. Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clin J Am Soc Nephrol. 2017 Apr 3;12(4):591-602. doi: 10.2215/CJN.08730816.

10. Lin YC, Lin YC, Chen HH, Chen TW, Hsu CC, Peng CC, Wu MS. Different effect of hypercholesterolemia on mortality in hemodialysis patients based on coronary artery disease or myocardial infarction. Lipids Health Dis. 2016 Dec 8;15(1):211. doi: 10.1186/s12944-016-0380-7.

11. Holzer M, Schilcher G, Curcic S, Trieb M, Ljubojevic S, Stojakovic T, Scharnagl H, Kopecky CM, Rosenkranz AR, Heinemann A, Marsche G. Dialysis Modalities and HDL Composition and Function. J Am Soc Nephrol. 2015 Sep;26(9):2267-76. doi: 10.1681/ASN.2014030309.

12. Lieberman AP, Swanson JA. High Cholesterol at the Heart of Phagolysosomal Damage. Cell Metab 2018; 27(3): 487-8. doi: 10.1016/j.cmet.2018.02.015

13. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15: 104-16. doi: 10.1038/nri3793.

 Rasmiena АA, Barlowa CK, Ng TW, Meikle PJ. High-density lipoprotein efficiently accepts surface but not internal oxidised lipids from oxidised low-density lipoprotein. Biochim Biophys Acta 2016;1861(2):69-77. doi: 10.1016/j.bbalip.2015.11.002

14. Kronenberg F. HDL in CKD – The Devil Is in the Detail. J Am Soc Nephrol 2018, 29: 1356-71.  doi: 10.1681/ASN.2017070798.

15. Yuksel M, Yildiz A, Tekbas E, Gunduz E, Ekinci A, Bilik MZ, et al. Paraoxonase and Arylesterase Activities in Dipper and Non-Dipper Prehypertensive Subjects. Medicine 2015; 94(17):786.  doi: 10.1097/MD.0000000000000786.

16. Uçar H, Coşkun M, Şeker T, Koç M, Gökdeniz T, Gözükara MY. Oxidative stress and paraoxonase 1 activity predict contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology 2015; 66(4):339-45. doi: 10.1177/0003319714533588.

17. Bains Y, Caccavello R, Kotani K, Gugliucci A.   Paraoxonase 1, HDL Subclasses and Post Surgery Acute Inflammation: A Pilot Study. Antioxidants (Basel, Switzerland) 2019; 8(6). doi: 10.3390/antiox8060192.

18. Shcheglova EV, Laipanova AI, Baikulova MK, Chotchaeva ZK, Rogova SS, Kolesnikov VN, et al. Genotypes and serum levels of apolipoprotein E and paraoxonase 1 in calcific aortic valve stenosis. Russian Journal of Cardiology. 2017;10:107-12.  doi: 10.15829/1560-4071-2017-10-107-112.

19.  Furlong CE, Marsillach J, Jarvik GP, Costa LG. Paraoxonases-1, -2 and -3: What are their functions? Chem Biol Interact. 2016;25(259):51-62. doi: 10.1016/j.cbi.2016.05.03.

20. Kowalska К, Socha Е, Milnerowicz H. The Role of Paraoxonase in Cardiovascular Diseases. Clin Lab Sci 2015;45(2):226-33.

  Kotur-Stevuljević J,  Vekić J, Stefanović A, Zeljković A, Ninić A, Ivanišević J, et al. Paraoxonase 1 and atherosclerosis-related diseases. Biofactors. 2019:1-13. doi: 10.1002/biof.1549.

21. Zhou C, Cao J, Shang L, Tong C, Hu H, Wang H, et al. Reduced Paraoxonase 1 Activity as a Marker for Severe Coronary Artery Disease. Dis Markers 2013; 35(2):97-103. doi: 10.1155/2013/816189.

22. Korol LV, Mygal LYa, Stepanova NM. Intensity of oxidative stress and activity of angiotensin converting enzyme in blood of patients with uncomplicated pyelonephritis. UkrBiochem J. 2017;89(2):99-105. doi: 10.15407/ubj89.02.09.

23. Stepanova N, Korol L, Burdeyna O. Oxidative Stress in Peritoneal Dialysis Patients: Association with the Dialysis Adequacy and Technique Survival (a prospective single-center observational study). Indian J Nephrol 2019; 29(5):309-16. doi: 10.4103/ijn.IJN_242_18.

24. Stepanova N, Burdeyna O. Association between Dyslipidemia and Peritoneal Dialysis Technique Survival. Open Access Macedonian Journal of Medical Sciences. 2019;7(15):2467-2473. doi: 10.3889/oamjms.2019.664  

25. Miljkovic M, Stefanovic A, Vekic J, Zeljkovic A, Gojkovic T, Simic-Ogrizovic S, et al. Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease. Clin Biochem 2018;60:52-8. doi: 10.1016/j.clinbiochem.2018.08.006.

26. Gordon SM, Remaley AT. High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis. Atherosclerosis 2017;259:104-13. doi: 10.1016/j.atherosclerosis.2016.11.015.

27. Ungurianu A, Margina D, Gradinaru D, Bacanu C, Ilie M, Tsitismpikoungurianu C, et al. Lipoprotein redox status evaluation as a marker of cardiovascular disease risk in patients with inflammatory disease. Mol Med Rep 2017;15:256-62. doi: 10.3892/mmr.2016.5972.

28. Mackness MI, Mackness B,Durrington PN. Paraoxonase and coronary heart disease. Atherosclerosis Supplements 2002;3(4):49–55. doi: 10.1016/s1567-5688(02)00046-6.

29. Deakin S, Moren X, James RW. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 2005;179(1):17–25. doi: 10.1016/j.atherosclerosis.2004.08.039. 

30. Gugliucci A, Kinugasa E, Ogata H, Caccavello R, Kimura S. Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL2 fraction and VLDL. Clin Chim Acta 2014; 430:9-14. doi: 10.1016/j.cca.2013.12.027.

31. Rajkovic MG, Rumora L, Juretic D, Grubisić TZ, Flegar-Mestrić Z, Vrkić Н, et al. Effect of non-genetic factors on paraoxonase 1 activity in patients undergoing hemodialysis. Clinical Biochemistry. 2010;43(18):1375-80. doi: 10.1016/j.clinbiochem.2010.08.024.

32. Rozenberg O, Shiner M, Aviram M, Hayek T. Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radic Biol Med 2008; 44(11):1951-9. doi: 10.1016/j.freeradbiomed.2008.02.012.

33. Prakash M, Shetty JK, Rao L, Sharma S, Rodrigues A, Prabhu R. Serum paraoxonase activity and protein thiols in chronic renal failure patients. Indian J Nephrol 2008;18(1):13–16. doi: 10.4103/0971-4065.41282.

34. Ikeda Y, Suehiro T, Itahara T, Inui Y, Chikazawa H, Inoue M, et al. Human serum paraoxonase concentration predicts cardiovascular mortality in hemodialysis patients. Clin Nephrol 2007;67(6):358–365 doi: 10.5414/cnp67358.

35. Ayan D, Şeneş M, Çaycı AB, Söylemez S, Eren N, Altuntaş Y, el al. Evaluation of Paraoxonase, Arylesterase, and Homocysteine Thiolactonase Activities in Patients with Diabetes and Incipient Diabetes Nephropathy. J Med Biochem 2019; 38(4):481-8. doi: 10.2478/jomb-2019-0014.

36. Saeed SA, Elsharkawy M, Elsaeed K, Fooda O. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int 2008; 12(4):471-9. doi: 10.1111/j.1542-4758.2008.00311.x.

37. Hammadah МН, Kalogeropoulos АР, Georgiopoulou VV, Weber М, Wu Y, Haze SL, et al. High-density lipoprotein-associated paraoxonase-1 activity for prediction of adverse outcomes in outpatients with chronic heart failure. Eur J Heart Fail. 2017; 19(6):748-55. doi: 10.1002/ejhf.777.

38. Kunutsor SK, Bakker SJ, James RW, Dullaart RP. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. Atherosclerosis. 2016;245:143-54. doi: 10.1016/j.atherosclerosis.2015.12.021.

39. Kunutsor SK, Kieneker LM, Bakker SJL, James RW, Dullaart RPF. Incident type 2 diabetes is associated with HDL, but not with its anti-oxidant constituent - paraoxonase-1: The prospective cohort PREVEND study. Metabolism. 2017; 73:43-51. doi: 10.1016/j.metabol.2017.05.004.


Abstract views: 594
PDF Downloads: 18975
Published
2019-12-23
How to Cite
Korol, L., Stepanova, N., & Vasylchenko, V. (2019). Arylesterase activity of paraoxonase 1 and intensity of oxidative processes in the blood of dialysis patients. Ukrainian Journal of Nephrology and Dialysis, (4(64), 30-38. https://doi.org/10.31450/ukrjnd.4(64).2019.05
Issue
No 4(64) (2019): Ukrainian Journal of Nephrology and Dialysis
Section
Original Papers